Tissue Regenix Group is a pioneering medical technology company with a global presence. They are at the forefront of developing regenerative products that have the potential to transform patient care. Their vision is to establish themselves as a leader in the science and innovation of regenerative medicine, committed to restoring patient function and vitality while delivering favorable health economic outcomes.

Regenerative medicine is their area of expertise. They explore the potential of tissue engineering to stimulate the body's own cells, triggering a natural recovery and enabling the regeneration of the patient's own tissues. Tissue Regenix Group utilizes their innovative platform technologies, dCELL® and BioRinse™, to address clinical needs in the regenerative medicine market.

Their focus is on developing regenerative products in the fields of BioSurgery, Orthopaedics, and Dental. These products aim to provide differentiated clinical outcomes and transform the treatment of patients in key clinical areas. With a sustainable and ethical business model, Tissue Regenix Group is dedicated to maintaining responsible practices.

Investors can find more information on their investment case and performance, while the media section offers deeper insights into the company